<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006886</url>
  </required_header>
  <id_info>
    <org_study_id>PSt-GFD</org_study_id>
    <nct_id>NCT04006886</nct_id>
  </id_info>
  <brief_title>Gluten-free Diet in Patients With Primary Sclerosing Cholangitis (PSC)</brief_title>
  <acronym>PSt-GFD</acronym>
  <official_title>Gluten-free Diet in Patients With Primary Sclerosing Cholangitis (PSC) - a Pilot-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Clinical Molecular Biology, Christian-Albrechts-University, Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gluten is a protein found in wheat and other cereals as barley and rye. It triggers an
      inflammatory reaction in the small-bowel of genetically predisposed persons.
      Alpha-amylase/trypsin inhibitors (ATIs) of wheat seem to be the responsible trigger of this
      intestinal Inflammation.

      Intestinal inflammation is connected to other extra-intestinal autoimmune inflammations like
      PSC (as f.ex. the association of PSC with inflammatory bowel disease proves).

      Hypothesis: Avoidance of ATIs through a gluten-free diet will reduce intestinal inflammation
      and thus also the the inflammatory activity in the liver.

      Proof of hypothesis:

        -  Pilot study with n=20 patients with PSC

        -  Explorative, open-label, mono-centric study

        -  Inclusion criteria: age 18-65, diagnosed PSC-associated colitis without relevant
           clinical activity after last coloscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 9, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of intestinal inflammatory activity</measure>
    <time_frame>2 months</time_frame>
    <description>Expression of pro-inflammatory cytokines in gut mucosa (Sigma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory activity of the liver</measure>
    <time_frame>2 months</time_frame>
    <description>alkaline phosphatase (AP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of inflammatory cells/markers in the blood</measure>
    <time_frame>2 months</time_frame>
    <description>stored blood samples, Pax-Gene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of symptoms with change of diet.</measure>
    <time_frame>2 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patients microbiota</measure>
    <time_frame>2 months (5 months with follow-up)</time_frame>
    <description>stool samples</description>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Reduction of Intestinal Inflammatory Activity</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gluten-free diet</intervention_name>
    <description>After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed PSC-associated colitis without relevant clinical activity after last
             coloscopy.

        Exclusion Criteria:

          -  patients with coeliac disease or wheat allergy

          -  patients with active colitis

          -  patients already on gluten-free diet

          -  liver transplanted patients

          -  patients also diagnosed with autoimmune hepatites (PSC-AIH overlap)

          -  coloscopy within 2 months before study

          -  Endoscopic retrograde cholangiopancreatography (ERCP) within 3 months before study

          -  antibiotics within 3 month before study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Marcus Tetzlaff</investigator_full_name>
    <investigator_title>study coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

